Previous 10 | Next 10 |
2024-01-04 13:51:02 ET More on BioNTech, Moderna, etc. Pfizer: If You Missed The Pandemic Entry, Here's Another Chance BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovatio...
2024-01-04 10:57:01 ET Summary Gilead Sciences is recovering from reduced Veklury (remdesivir) revenue following the height of the COVID-19 pandemic. The company, however, is making progress in HIV product sales and oncology, the latter it expects to make up one-third of its busin...
2023-12-31 06:29:54 ET Summary Gilead Sciences has seen stagnant sales growth over the past decade, but has potential for future growth in its oncology and virology programs. The company has a relatively high dividend yield of 3.7% and a safe payout ratio, allowing for potential d...
2023-12-28 13:02:19 ET More on Gilead Sciences Gilead Sciences Is Building A Diversified Portfolio Gilead Sciences, Inc. (GILD) Presents at Piper Sandler 35th Annual Healthcare Conference (Transcript) Gilead Sciences, Inc. (GILD) Presents at 6th Annual Evercore ISI H...
2023-12-26 07:02:44 ET More on BioNTech, Moderna, etc. BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Pfizer: Buy The Panic Pfizer Is Not Cheap, And The 5.7% Yield Is Not As Safe As You Might Think Citi puts Pfizer on catalyst watch afte...
2023-12-24 08:53:45 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2023-12-21 08:50:38 ET DENVER, Colo., Dec 21, 2023 ( www.247marketnews.com )- HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported, this morning, that Gilead Sciences, Inc. (NASDAQ: GILD) purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of...
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola PR Newswire Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir...
2023-12-20 05:52:06 ET Stock futures were little changed on Wednesday after the major averages extended the strong year-end rally, as investors leaned towards the idea that the Fed is managing a soft economic slowdown, despite efforts by Fed policymakers to temper expectations for rate...
2023-12-19 17:11:10 ET DENVER, Colo., Dec. 19, 2023 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Compugen Ltd (NASDAQ: CGEN), Gilead Sciences, Inc. (NASDAQ: GILD), Infobird Co Ltd (NASDAQ: IFBD), and Panbela Therapeutics Inc (NASDAQ: PBLA). Comp...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...